Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

301. Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and D-dimer

Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical Model and D-dimer PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

302. Strategies incorporating spiral CT for the diagnosis of acute pulmonary embolism: a cost-effectiveness analysis

research should focus on improvements in the estimation of spiral CT properties. Source of funding Part funded by a Chercheur Boursier-Clinicien award from the Fonds de la Recherche en Sante du Quebec. Bibliographic details Paterson D I, Schwartzman K. Strategies incorporating spiral CT for the diagnosis of acute pulmonary embolism: a cost-effectiveness analysis. Chest 2001; 119(6): 1791-1800 PubMedID Other publications of related interest The PIOPED investigators. Value of ventilation/perfusion scan (...) Strategies incorporating spiral CT for the diagnosis of acute pulmonary embolism: a cost-effectiveness analysis Strategies incorporating spiral CT for the diagnosis of acute pulmonary embolism: a cost-effectiveness analysis Strategies incorporating spiral CT for the diagnosis of acute pulmonary embolism: a cost-effectiveness analysis Paterson D I, Schwartzman K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

2001 NHS Economic Evaluation Database.

303. Cost-effectiveness of currently accepted strategies for pulmonary embolism diagnosis

Cost-effectiveness of currently accepted strategies for pulmonary embolism diagnosis Cost-effectiveness of currently accepted strategies for pulmonary embolism diagnosis Cost-effectiveness of currently accepted strategies for pulmonary embolism diagnosis Hull R D, Pineo G F, Stein P D, Mah A F, Butcher R S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three alternative diagnostic strategies for diagnosing pulmonary embolism (PE) were evaluated. All strategies began with a ventilation-perfusion scan, and were then followed by a variety of different strategies in patients with a nondiagnostic result: ventilation-perfusion scans and pulmonary angiography; ventilation-perfusion scans, single noninvasive leg test, and pulmonary

2001 NHS Economic Evaluation Database.

304. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. (Abstract)

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Previous trials of antiplatelet therapy for the prevention of venous thromboembolism have individually been inconclusive, but a meta-analysis of their results indicated reductions in the risks of deep-vein thrombosis and of pulmonary embolism in various high-risk groups. The aim of this large randomised placebo-controlled trial was to confirm or refute these apparent (...) the patients with hip fracture, allocation to aspirin produced proportional reductions in pulmonary embolism of 43% (95% CI 18-60; p=0.002) and in symptomatic deep-vein thrombosis of 29% (3-48; p=0.03). Pulmonary embolism or deep-vein thrombosis was confirmed in 105 (1.6%) of 6679 patients assigned aspirin compared with 165 (2.5%) of 6677 assigned placebo, which represents an absolute reduction of 9 (SE 2) per 1000 and a proportional reduction of 36% (19-50; p=0.0003). Similar proportional effects were

2000 Lancet Controlled trial quality: predicted high

305. The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism

The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism Mullins M D, Becker D M, Hagspiel K D, Philbrick J T Authors' objectives To evaluate the evidence for the use of spiral volumetric computed tomography (SVCT) in the diagnosis of acute pulmonary embolism (PE). Searching MEDLINE (from (...) a large multi-centre trial and specific investigation of the sensitivity of SVCT in the detection of small subsegmental emboli'. Bibliographic details Mullins M D, Becker D M, Hagspiel K D, Philbrick J T. The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism. Archives of Internal Medicine 2000; 160(3): 293-298 PubMedID Original Paper URL Other publications of related interest Remy-Jardin M, Wattinne L, Giraud F. Central pulmonary thromboembolism: diagnosis

2000 DARE.

306. Effect of D-dimer testing on the diagnostic strategy of suspected pulmonary embolism: an observational study of practice patterns and costs

Effect of D-dimer testing on the diagnostic strategy of suspected pulmonary embolism: an observational study of practice patterns and costs Effect of D-dimer testing on the diagnostic strategy of suspected pulmonary embolism: an observational study of practice patterns and costs Effect of D-dimer testing on the diagnostic strategy of suspected pulmonary embolism: an observational study of practice patterns and costs Lebrun E, Maitre B, Grenier-Sennelier C, Katsahian S, Gouault-Heilmann M (...) , Vasile N, Meignan M, Housset B, Durand-Zaleski I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of D-dimer testing for the diagnosis of suspected pulmonary embolism. Type of intervention Diagnosis. Economic study type Cost

2000 NHS Economic Evaluation Database.

307. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence

of systemic hypoperfusion. Bibliographic details Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest 1999; 115(6): 1695-1707 PubMedID DOI Original Paper URL Other publications of related interest 1. Cook DJ, Guyatt GH, Laupacis, et al. Clinical recommendations using levels of evidence for anithrombotic agents. Chest 1995; 108(suppl): 227S-30S. Indexing Status Subject indexing assigned by NLM MeSH Anticoagulants /therapeutic use; Decision (...) Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence Arcasoy SM, Kreit JW Authors' objectives To provide a comprehensive and systematic review of studies evaluating thrombolytic therapy of patients with pulmonary embolism (PE). Seven objectives were identified: 1. What are the proven

1999 DARE.

308. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. (Abstract)

Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. The most serious complication of deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE) is fatal PE. However, reliable estimates as to the risk of fatal PE in patients with treated DVT or PE are lacking.To provide reliable estimates of the risk of fatal PE and the case-fatality rate of recurrent DVT or PE among patients presenting with symptomatic DVT or PE, during and following 3 months of anticoagulant

1998 JAMA

309. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. (Abstract)

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. The efficacy and safety of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis is still a matter of debate.Using a two-by-two factorial design, we randomly assigned 400 patients with proximal deep-vein thrombosis who were at risk (...) for pulmonary embolism to receive a vena caval filter (200 patients) or no filter (200 patients), and to receive low-molecular-weight heparin (enoxaparin, 195 patients) or unfractionated heparin (205 patients). The rates of recurrent venous thromboembolism, death, and major bleeding were analyzed at day 12 and at two years.At day 12, two patients assigned to receive filters (1.1 percent), as compared with nine patients assigned to receive no filters (4.8 percent), had had symptomatic or asymptomatic

1998 NEJM Controlled trial quality: predicted high

310. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty

Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis (...) and pulmonary embolism following total hip or knee arthroplasty Anderson D R, O'Brien B, Nagpal S, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Anderson D R, O'Brien B, Nagpal S, et al. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following

1998 Health Technology Assessment (HTA) Database.

311. Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care

. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of an artificial neural network (ANN) to diagnose and determine treatment strategies in patients with suspected acute pulmonary embolism. The network was trained to predict the probability of pulmonary embolism by using physicians' findings from ventilation-perfusion lung scans and chest (...) Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care Acute pulmonary embolism: cost-effectiveness analysis of the effect of artificial neural networks on patient care Tourassi G D, Floyd C E, Coleman R E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED

1998 NHS Economic Evaluation Database.

312. Cost-effective diagnostic algorithms in pulmonary embolism: an updated analysis

Cost-effective diagnostic algorithms in pulmonary embolism: an updated analysis Cost-effective diagnostic algorithms in pulmonary embolism: an updated analysis Cost-effective diagnostic algorithms in pulmonary embolism: an updated analysis van Erkel A R, Pattynama P M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Diagnosis of pulmonary embolism (PE). Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Persons with suspected PE. Setting The setting was Leiden University Medical Centre, Leiden, The Netherlands. Dates to which data relate Effectiveness data were collected from studies previously published between 1985 and 1997. The dates of resource use data and the price

1998 NHS Economic Evaluation Database.

313. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. (Abstract)

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. Low-molecular-weight heparin appears to be at least as effective and safe as standard, unfractionated heparin for the treatment of deep-vein thrombosis, but only limited data are available on the use of low-molecular-weight heparin to treat acute symptomatic pulmonary embolism.We randomly assigned (...) 612 patients with symptomatic pulmonary embolism who did not require thrombolytic therapy or embolectomy to either subcutaneous low-molecular-weight heparin (tinzaparin) given once daily in a fixed dose or adjusted-dose, intravenous unfractionated heparin. Oral anticoagulant therapy was begun between the first and the third day and was given for at least three months. We compared the treatments at day 8 and day 90 with respect to a combined end point of recurrent thromboembolism, major bleeding

1997 NEJM Controlled trial quality: uncertain

314. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy

Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Lloyd A, Aitken J A, Hoffmeyer U K, Kelso E J (...) , Wakerly E C, Barber N D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of nadroparin calcium (a low-molecular weight heparin (LMWH)) in the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). Type

1997 NHS Economic Evaluation Database.

315. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. (Abstract)

Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Fatal pulmonary embolism and other thromboembolic complications are common in hospital inpatients. However, there is little evidence on the routine use of pharmacological thromboprophylaxis in non-surgical patients. We assessed the efficacy and safety of low-dose heparin in the prevention of hospital-acquired, clinically relevant (...) , fatal pulmonary embolism in patients with infectious diseases.Our study used the postrandomisation consent design. 19,751 consecutive patients, aged 55 years or older, admitted to departments of infectious diseases in six Swedish hospitals, were screened for inclusion in the randomised, controlled, unblinded, multicentre trial. Of the eligible patients, 5776 were assigned subcutaneous standard heparin (5000 IU every 12 h) until hospital discharge or for a maximum of 3 weeks; 5917 were assigned

1996 Lancet Controlled trial quality: predicted high

316. The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism

The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism Michel B C, Seerden R J, Rutten F F, Van Beek E J, Buller H R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Diagnostic strategy (and anticoagulant treatment in case of diagnosis of pulmonary embolism) recommended by the Dutch consensus meeting in 1992 consisting of ventilation-perfusion (VQ) scan followed by ultrasound of lower extremity, followed by lung angiography. Comparison strategies also may include a D-dimer test (marker of clot

1996 NHS Economic Evaluation Database.

317. Ultrasound at scintigraphic intermediate probability of pulmonary embolism

Ultrasound at scintigraphic intermediate probability of pulmonary embolism Ultrasound at scintigraphic intermediate probability of pulmonary embolism Ultrasound at scintigraphic intermediate probability of pulmonary embolism Christiansen F, Kellerth T, Andersson T, Ragnarsson A, Hjortevang F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ultrasound as an additional diagnostic examination to 'intermediate probability of pulmonary embolism (PE)' established by ventilation/perfusion(V/Q) scintigraphy. Type of intervention Secondary prevention; diagnosis. Economic study type Cost-effectiveness analysis. Study population Patients aged 18 years or older with a diagnosis of "intermediate probability of PE" according

1996 NHS Economic Evaluation Database.

318. Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis

Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis Spiral CT angiography for suspected pulmonary embolism: a cost-effectiveness analysis van Erkel A R, van Rossum A B, Bloem J L, Klevit J, Pattynama P M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) improvements in the cost-effectiveness of the diagnosis of suspected pulmonary embolism. CRD COMMENTARY - Selection of comparators The selection of comparators was appropriate and clearly justified in this case. Validity of estimate of measure of benefit Estimates were derived from a systematic review of previously published studies. The techniques used to pool the data were not specified in the report. Validity of estimate of costs Costs included in the analysis were those incurred only by the treating

1996 NHS Economic Evaluation Database.

319. The role of plasma D-dimer concentration in the exclusion of pulmonary embolism

The role of plasma D-dimer concentration in the exclusion of pulmonary embolism The role of plasma D-dimer concentration in the exclusion of pulmonary embolism The role of plasma D-dimer concentration in the exclusion of pulmonary embolism van Beek E J, Schenk B E, Michel B C, van den Ende B, Brandjes D P, van der Heide Y T, Bossuyt P M, Buller H R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Plasma D-dimer concentration in the exclusion of pulmonary embolism. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Consecutive patients (both in- and outpatients) who underwent diagnostic work-up for clinically suspected pulmonary embolism. Setting The practice setting was two

1996 NHS Economic Evaluation Database.

320. Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients

. Implications of the review for practice and research Prophylactic antiplatelet therapy should be considered in surgical and medical patients who are at high risk of venous thrombosis and pulmonary embolism. Funding Medical Research Council; Chest, Heart and Stroke Association; Edinburgh University; Clinical Trial Service Unit; British Heart Foundation; Imperial Cancer Research Fund; various pharmaceutical companies. Bibliographic details Antiplatelet Trialists' Collaboration. Collaborative overview (...) Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis

1994 DARE.